International Conference on Lewy Body Dementia Research

International Congress on Lewy Body Dementia Research

La misión de Asinlewy es prestar apoyos para una enfermedad que necesita a psiquiatras, neurólogos, neuropsicólogos, fisioterapeutas y terapeutas ocupaciones, sin olvidar el papel de las enfermeras.

¿Por qué es necesario el Congreso INLEWY?

Aproximadamente el 25% de todos los casos de demencia mundial, cursan con demencia por cuerpos de Lewy. Sin embargo, el diagnóstico, manejo y tratamiento de estos pacientes sigue siendo un enorme desafío para la comunidad científica.

Por todo ello, es de vital importancia desarrollar un evento científico que reúna a los mayores expertos a nivel internacional en DCL, con otros expertos a nivel multidisciplinar, para traer los últimos avances y el futuro de la investigación y manejo en DCL, con el fin de compartir experiencia y fomentar nuevas redes de colaboración, con nuevos enfoques que permitan investigar en todos los aspectos de la DCL, para poder mejorar los fatídicos datos actuales y corregir el grave déficit en investigación, que sufre esta importante demencia.

Programa del Congreso

*Tenga en cuenta que éste es el programa preliminar; los horarios y los títulos están sujetos a cambios.

Miércoles 19 (Biomarcadores)

10:00 – Acto de apertura y lanzamiento del congreso por parte de miembros de la dirección universitaria y la presidencia de la asociación
10:30 – Dr. Daniel Alcolea (Unidad de memoria Hospital Sant Pau (Spain))- «Diagnóstico de Demencia con Cuerpos de Lewy en la era de los biomarcadores
11:30 – Sesión de poster y pausa café
12:15 – 4 presentaciones orales
14:00 – Hora de la comida
16:00 – Dra. Estrella Morenas (Hospital Universitario 12 de octubre (Spain))- «Biomarcadores en investigación / Retos en el estudio de la DLB»
17:00 – Sesión de carteles y pausa café
17:45 – Katrin Beyer (Instituto de investigación Germans Tries y Pujol (Spain))
20:00 – Cóctel de Bienvenida

Jueves 20 (Descubrimiento de fármacos y perspectivas futuras)

09:30 – Dr. Ana Martínez (Centro de investigaciones biomédicas -Margarita Salas)
10:30 – 4 presentaciones
11:30 – Sesión de poster y pausa para café
12:00 – Sonia Contera (University of Oxford)
13:00 – 4 presentaciones orales
12:00 – Hora de la comida
16:00 – Mesa redonda «De los futuros biomarcadores a las nuevas perspectivas terapéuticas»
17:00 – Sesión de carteles y pausa para café
17:45 – Dr. Alberto Rábano (Fundación Alzheimer Reina Sofía) «Donación de tejido cerebral en demencia con cuerpos de Lewy: extracción, diagnóstico y clasificación
20:00 – Cena de Gala

Viernes 21 (Otros enfoques: nutracéuticos, fitoterapia)

10:00 – Dr José Ignacio Lao Villadóniga (Genomic Genetics): La medicina genómica: clave de la medicina de precisión aplicada al uso de fármacos y nutracéuticos.
11:00 – Gianfranco Diretto (Research Scientist, italian Agency for New Technologies, Energy and Sustainable Development (ENEA) (Italy)): Approaches of plant metanolic engieering for the accumulation of neuroprotective compounds
11:45 – Pausa café
12:15 – Prof. Silvia Bisti (University of L’Aquila (Italy): The possibilities of the uses of saffron in body lewy dementia
13:15 – Prof María Lourdes Gómez Gómez (Universidad de Castilla La Mancha (Spain))
14:00 – Acto de clausura

Speakers

Dr. Ana Martínez Gil

Dr. Ana Martinez is Research Professor at the Biological Research Center (CIB) of Spanish National Council for Research (CSIC). Her interest is focused on neurodegenerative disorders, leading numerous research projects on the medicinal chemistry and rational drug design of new drugs for Alzheimer’s and Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Her research is in close contact with biopharmaceutical companies for technology transfer. Since February 2002 till January 2008, she was R&D Director of NeuroPharma, after called NOSCIRA. During this period, two of her research projects reached clinical trials as disease modifying agents for Alzheimer’s disease. In 2008, she returned to her academic laboratory where several projects have been developed in a private-public environment. She is author of more than a three hundred and fifty scientific publications, more than fourty families of patents in the field and editor of several books. She acts as scientific advisory board for several SMEs in the biotech field and she is founder of ANKAR PHARMA and MOLEFY, which goal is full the gap between basic drug discovery research and clinical trials for neurodegenerative diseases mainly for ALS. In 2022 she was awarded with the National Research prize Juan de la Cierva by the Science Minister and the Prize to the best National patent by the OEPM, in 2023 she received the “Margarita Salas” medal to excellence in scientific supervision by CSIC, and the prize to the best researcher of the year by Invertia.

Dr. Katrin Beyer

Katrin Beyer has been working for more than 25 years in the field of neurodegenerative dementias. After the discovery of the alpha-synuclein gene and its importance for Lewy body diseases, she started the study of transcriptomic changes in post-mortem brain. Over the past years, she has focused especially on dementia with Lewy bodies (DLB), which is characterized by a significant overlap with Alzheimer’s disease and up to 80% of cases are undiagnosed or misdiagnosed as Alzheimer’s.

Thus, the Genomics and Transcriptomics of Synucleinopathies (GTS) group led by Katrin Beyer is committed to the search for peripheral biomarkers which permit a reliable DLB diagnosis. Once accurate diagnostic tests are developed, clinical trials for AD and DLB will avoid inclusion of misdiagnosed patients and, accordingly, speed up the development of specific therapies.
Katrin Beyer has published more than 70 research papers in international peer-reviewed journals. All studies are carried out in the context of research projects funded by several state and regional agencies, including the Spanish Ministry of Health and Innovation.
Katrin Beyer has developed NGS based diagnostic panels for dementia and parkinsonism which are being used in Neurology departments to facilitate clinical diagnosis. Finally, she is the author of four patents, two for the identification of specific DLB subgroups, one to monitor the treatment with anti-alpha-synuclein aggregation therapies, and one for patient stratification. Currently, the two latter are further developed to provide useful diagnostic tools for the clinical practice.

Dr. Daniel Alcolea

Dr. Daniel Alcolea is a neurologist in the Memory Unit at Hospital Sant Pau (Barcelona) and the coordinator of its biochemical marker research platform. His research focuses on the clinical application and validation of biomarkers in cerebrospinal fluid and blood for neurodegenerative diseases. These studies have resulted in over 170 publications and 10,000 citations. Specializing in dementia with Lewy bodies, he has participated in national and European consortia. Additionally, he combines his clinical and research work with teaching at the Autonomous University of Barcelona.

Sonia Contera

Sonia Contera is a Professor of Biological Physics at the University of Oxford (UK).

Her work is on the physics at the interface of biology and nanotechnology; she uses physics both to measure and model biological behaviour/properties from the nanoscale up, and she has an interest in understanding the emergence of “biological shapes”.

Currently, she is working on a novel surface acoustic wave (SAW) sensor for monitoring neuronal activity, which is able to measure periodic signals from neurons from the Hz to the GHz range.

She is also interested in how physics can help to identify and detect the causes of brain diseases for diagnostic/treatments, e.g. by understanding the physics underpinning multiscale circular causality in tissues using e.g. the framework of thermodynamics/statistical physics.

She is the author of “Nano Comes to Life: How Nanotechnology is Transforming Medicine and the Future of Biology”

Dr. Estrella Morenas Rodríguez

Dr. Estrella Morenas-Rodríguez is a clinical neurologist and neuroscientist specializing in neurodegenerative diseases, with a particular emphasis on dementia with Lewy bodies (DLB). She earned her medical degree from the Universidad Complutense de Madrid and completed her Neurology residency at Hospital de la Santa Creu i Sant Pau in Barcelona. She holds a Ph.D. in Neuroscience from the Universitat Autònoma de Barcelona, where her dissertation focused on the clinical and biological heterogeneity of DLB, leading to the identification of three distinct clinical subtypes.

During her postdoctoral fellowship at the German Center for Neurodegenerative Diseases (DZNE) in Munich, Dr. Morenas-Rodríguez investigated TREM2-dependent microglial activation in neurodegenerative diseases through a biomarker approach.

Dr. José Ignacio Lao Villadóniga

Dr. Lao, Medical Director of Genomic Genetics International, is a reference in genetics and anti-aging medicine. He has been awarded by the World Academy of Neural Therapy and is an active member of several scientific societies.

He has stood out for his research in neurodegeneration, identifying the first mutation in the PSEN2 gene related to Alzheimer’s disease in Spain. He has also worked in the study of Fragile X syndrome and spinocerebellar ataxia.

His innovative approach in personalized medicine, based on pharmacogenetics and nutritional genomics, seeks to improve the treatment of diseases through protocols adapted to the genetic profile of patients.

Abstract

El Congreso Internacional Sobre la Investigación de la Demencia con Cuerpos de Lewy invita a enviar abstracts para su presentación tanto oral como en forma de póster. El congreso tendrá lugar del 19 al 21 de febrero de 2025 en Albacete, España.

Para obtener el template del abstract: